Background & Aims Controlled real-world evidence on nonmedical switching from reference ustekinumab to biosimilars in Crohn’s disease (CD) is limited. We compared 6-month outcomes after switching vs continued reference treatment. Methods In this prospective observational cohort at 18 Italian centers, adults with CD in clinical remission (Harvey-Bradshaw Index <5) and steroid-free for ≥8 months of reference ustekinumab, underwent a procurement-driven switch to 1 of 3 approved biosimilars or continued reference treatment. The expanded clinical success end point required clinical remission without systemic corticosteroids, anti-interleukin12 or 23 discontinuation, inflammatory bowel disease–related hospitalization, or intestinal surgery. The protocol-specified noninferiority margin was −15%. Results Among 462 patients, 337 switched and 125 continued reference ustekinumab; only 4 (0.9%) received every-4-week dosing. Expanded clinical success occurred in 306 of 332 switched patients (92.2%) and 114 of 123 controls (92.7%; risk difference, −0.5%, 95% confidence interval, −5.9 to 4.9), meeting the noninferiority criterion. Results were consistent for the protocol-defined 3-component composite and after propensity-score weighting. Biosimilar persistence was 93.7%; switch-back occurred in 1.2%. Two adverse events were reported after switching. Conclusions In clinically stable CD, the observed 6-month effectiveness and safety after procurement-driven ustekinumab biosimilar switching were similar to continued reference treatment. Longer-term studies, particularly in patients receiving every-4-week dosing, are needed.
Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: The USBIOS-Italian Group for the Study of Inflammatory Bowel Disease Study / Ribaldone, D.G., Tribocco, E., Scaldaferri, F., Murgiano, M., Parello, S., Di Vincenzo, F., Del Gaudio, A., Puca, P., Napolitano, D., Papa, A., Lopetuso, L.R., Laterza, L., Bezzio, C., Armuzzi, A., Farinola, V., Savarino, E.V., Zingone, F., Barberio, B., Bertin, L., Todeschini, A., et al.. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - ELETTRONICO. - (2026), pp. 0-0. [10.1016/j.cgh.2026.08.014]
Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: The USBIOS-Italian Group for the Study of Inflammatory Bowel Disease Study
Dragoni, Gabriele;
2026
Abstract
Background & Aims Controlled real-world evidence on nonmedical switching from reference ustekinumab to biosimilars in Crohn’s disease (CD) is limited. We compared 6-month outcomes after switching vs continued reference treatment. Methods In this prospective observational cohort at 18 Italian centers, adults with CD in clinical remission (Harvey-Bradshaw Index <5) and steroid-free for ≥8 months of reference ustekinumab, underwent a procurement-driven switch to 1 of 3 approved biosimilars or continued reference treatment. The expanded clinical success end point required clinical remission without systemic corticosteroids, anti-interleukin12 or 23 discontinuation, inflammatory bowel disease–related hospitalization, or intestinal surgery. The protocol-specified noninferiority margin was −15%. Results Among 462 patients, 337 switched and 125 continued reference ustekinumab; only 4 (0.9%) received every-4-week dosing. Expanded clinical success occurred in 306 of 332 switched patients (92.2%) and 114 of 123 controls (92.7%; risk difference, −0.5%, 95% confidence interval, −5.9 to 4.9), meeting the noninferiority criterion. Results were consistent for the protocol-defined 3-component composite and after propensity-score weighting. Biosimilar persistence was 93.7%; switch-back occurred in 1.2%. Two adverse events were reported after switching. Conclusions In clinically stable CD, the observed 6-month effectiveness and safety after procurement-driven ustekinumab biosimilar switching were similar to continued reference treatment. Longer-term studies, particularly in patients receiving every-4-week dosing, are needed.| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS1542356526006373.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
1.66 MB
Formato
Adobe PDF
|
1.66 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



